Kennedy PhRMA-Friendly Agenda Includes Wariness Of Waxman/Hatch Reform
Executive Summary
Waxman/Hatch reform should not be undertaken without setting clear boundaries, Sen. Kennedy (D-Mass.) told the Pharmaceutical Research & Manufacturers of America annual meeting in Naples, Fla., March 31.
You may also be interested in...
Senate Transition Puts Kennedy Atop Health: Rx Marketing In Spotlight?
The return of Sen. Kennedy (D-Mass.) to the chairmanship of the Senate Health Committee could open a pipeline for the grand jury investigations of pharmaceutical marketing to feed into the Washington political debate.
Senate Transition Puts Kennedy Atop Health: Rx Marketing In Spotlight?
The return of Sen. Kennedy (D-Mass.) to the chairmanship of the Senate Health Committee could open a pipeline for the grand jury investigations of pharmaceutical marketing to feed into the Washington political debate.
PBM Rules Are Pivotal Point Of Medicare Rx Debate, Breaux Tells PhRMA
The structure of competition among PBMs is a key point for industry to weigh in on during the Medicare drug benefit debate, Sen. Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 31 in Naples, Fla.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: